irinotecan has been researched along with abt-737 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, S; Okumura, K; Sinicrope, FA | 1 |
| Cho, SY; Han, JY; Kang, J; Kang, W; Kwon, JY; Lee, A; Lee, C; Min, S; Park, H | 1 |
| Chi, SW; Lee, B; Lee, SO; Min, JA; Nashed, A; Yi, GS; Yoo, JC | 1 |
1 review(s) available for irinotecan and abt-737
| Article | Year |
|---|---|
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts.
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Biphenyl Compounds; Camptothecin; Drug Synergism; Graft Survival; Humans; Irinotecan; Mice; Mice, Nude; Mice, SCID; Molecular Targeted Therapy; Nitrophenols; Piperazines; Precision Medicine; Stomach Neoplasms; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
2 other study(ies) available for irinotecan and abt-737
| Article | Year |
|---|---|
Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Topics: Apoptosis; bcl-X Protein; Biphenyl Compounds; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Humans; Irinotecan; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2008 |
A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.
Topics: Apoptosis; Bcl-2-Like Protein 11; bcl-X Protein; Binding Sites; Biphenyl Compounds; Cell Cycle Checkpoints; Cell Proliferation; DNA Topoisomerases, Type I; HCT116 Cells; Humans; Imidazoles; Irinotecan; Models, Molecular; Nitrophenols; Nuclear Magnetic Resonance, Biomolecular; Piperazines; Protein Binding; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Sulfonamides; Tumor Suppressor Protein p53 | 2019 |